Hermida Ramón C, Hermida-Ayala Ramón G, Smolensky Michael
Laboratorio de Bioingeniería y Cronobiología, Atlantic Research Center for Information and Communication Technologies (atlanTTic), Universidad de Vigo, Vigo, España; Department of Biomedical Engineering, Cockrell School of Engineering, The University of Texas at Austin, Austin, Texas, Estados Unidos.
Chief Parmacology Officer (CPO), Circadian Ambulatory Technology & Diagnostics (CAT&D), Santiago de Compostela, La Coruña, España.
Med Clin (Barc). 2020 Jun 26;154(12):505-511. doi: 10.1016/j.medcli.2020.02.004. Epub 2020 Apr 23.
Numerous prospective studies establish that elevated asleep blood pressure (BP) constitutes a significant cardiovascular disease (CVD) risk factor, irrespective of daytime office BP measurements or awake and 24h BP measurements. Moreover, except for a small number of studies with flawed methodology, multiple clinical trials of high consistency document significantly better BP-lowering efficacy of hypertension medication and their combinations when ingested at bedtime compared to upon awakening as is customary. Additionally, recent trials conclude bedtime hypertension chronotherapy markedly reduces CVD risk not only in the general population, but also in more vulnerable patients of advanced age, with kidney disease, diabetes, or resistant hypertension. Collectively, these results call for a new definition of true arterial hypertension and its proper diagnosis and management.
众多前瞻性研究表明,睡眠时血压升高是心血管疾病(CVD)的一个重要危险因素,无论日间诊室血压测量值或清醒及24小时血压测量值如何。此外,除少数方法有缺陷的研究外,多项高度一致的临床试验证明,与按常规在醒来时服药相比,高血压药物及其组合在睡前服用时的降压效果显著更好。此外,近期试验得出结论,就寝时间高血压时间疗法不仅能显著降低普通人群的CVD风险,还能降低高龄、患有肾脏疾病、糖尿病或顽固性高血压等更脆弱患者的CVD风险。总体而言,这些结果呼吁对真性动脉高血压进行新的定义及其正确的诊断和管理。